JP2012532106A5 - - Google Patents

Download PDF

Info

Publication number
JP2012532106A5
JP2012532106A5 JP2012517814A JP2012517814A JP2012532106A5 JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5 JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012517814 A JP2012517814 A JP 2012517814A JP 2012532106 A5 JP2012532106 A5 JP 2012532106A5
Authority
JP
Japan
Prior art keywords
methyl
phenyl
trifluoromethyl
trans
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012517814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012532106A (ja
JP5689875B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/040125 external-priority patent/WO2011002696A1/en
Publication of JP2012532106A publication Critical patent/JP2012532106A/ja
Publication of JP2012532106A5 publication Critical patent/JP2012532106A5/ja
Application granted granted Critical
Publication of JP5689875B2 publication Critical patent/JP5689875B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012517814A 2009-06-30 2010-06-28 トランス−4−[[(5s)−5−[[[3,5−ビス(トリフルオロメチル)フェニル]メチル](2−メチル−2h−テトラゾール−5−イル)アミノ]−2,3,4,5−テトラヒドロ−7,9−ジメチル−1h−1−ベンゾアゼピン−1−イル]メチル]−シクロヘキサンカルボン酸 Expired - Fee Related JP5689875B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
US61/221,708 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (3)

Publication Number Publication Date
JP2012532106A JP2012532106A (ja) 2012-12-13
JP2012532106A5 true JP2012532106A5 (https=) 2013-08-15
JP5689875B2 JP5689875B2 (ja) 2015-03-25

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012517814A Expired - Fee Related JP5689875B2 (ja) 2009-06-30 2010-06-28 トランス−4−[[(5s)−5−[[[3,5−ビス(トリフルオロメチル)フェニル]メチル](2−メチル−2h−テトラゾール−5−イル)アミノ]−2,3,4,5−テトラヒドロ−7,9−ジメチル−1h−1−ベンゾアゼピン−1−イル]メチル]−シクロヘキサンカルボン酸

Country Status (37)

Country Link
US (2) US8329688B2 (https=)
EP (1) EP2448933B1 (https=)
JP (1) JP5689875B2 (https=)
KR (1) KR101404893B1 (https=)
CN (1) CN102639528B (https=)
AR (1) AR077208A1 (https=)
AU (1) AU2010266537B2 (https=)
BR (1) BRPI1011931A2 (https=)
CA (1) CA2764425C (https=)
CL (1) CL2011003263A1 (https=)
CO (1) CO6480934A2 (https=)
CR (1) CR20110669A (https=)
DK (1) DK2448933T3 (https=)
DO (1) DOP2011000405A (https=)
EA (1) EA020600B1 (https=)
EC (1) ECSP11011551A (https=)
ES (1) ES2435293T3 (https=)
GT (1) GT201100321A (https=)
HR (1) HRP20130950T1 (https=)
IL (1) IL216655A (https=)
JO (1) JO2867B1 (https=)
MA (1) MA33385B1 (https=)
ME (1) ME01606B (https=)
MX (1) MX2011014024A (https=)
MY (1) MY157121A (https=)
NZ (1) NZ596820A (https=)
PE (1) PE20120538A1 (https=)
PL (1) PL2448933T3 (https=)
PT (1) PT2448933E (https=)
RS (1) RS52988B (https=)
SG (1) SG177413A1 (https=)
SI (1) SI2448933T1 (https=)
TN (1) TN2011000638A1 (https=)
TW (1) TWI450896B (https=)
UA (1) UA109409C2 (https=)
WO (1) WO2011002696A1 (https=)
ZA (1) ZA201108707B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
WO2014119947A1 (en) 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (https=) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
ATE316957T1 (de) 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Similar Documents

Publication Publication Date Title
JP2012532106A5 (https=)
JP2014501282A5 (https=)
HRP20130950T1 (hr) Trans-4-[[(5s)-5-[[[3,5-bis(trifluormetil)fenil]metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]cikloheksankarboksilna kiselina
JP2017504576A5 (https=)
JP2013521301A5 (https=)
RU2016123382A (ru) Твердые формы { [5-(3-хлорфенил)-3-гидроксипиридин-2-карбонил]амино} уксусной кислоты, их композиции и применения
JP2013538849A5 (https=)
CA2958139A1 (en) Solid state forms of ibrutinib
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2015520140A5 (https=)
WO2012088607A1 (en) Process for treprostinil salt preparation
JP2008505171A5 (https=)
ME02655B (me) Spojevi dimetilbenzojeve kiseline, korisni u liječenju upalnih stanja
EP3229814A1 (en) Co-crystal of dapagliflozin with citric acid
JP2015502371A5 (https=)
JP2007505879A (ja) 既知の抗高脂血症剤の多形体
WO2010065443A1 (en) Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
JP6748123B2 (ja) サクビトリルカルシウム塩
AU2019221837B2 (en) Agents and methods for treating dysproliferative diseases
HRP20170023T1 (hr) Kristalni oblik pemirolasta
JP2015512381A5 (https=)
HRP20161186T1 (hr) Soli heterociklamidno supstituiranih imidazola sa sulfonskim kiselinama
JP2019524829A5 (https=)
US7947842B2 (en) Hydrates of alkaline-earth salts of irbesartan and the preparation thereof
RU2014127478A (ru) Кристаллические формы[(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты